High-risk M0 prostate cancer - clinical case

 

Doctor hierarchy

Source: Roberts, E. (2021, November 29). Guide to the Doctor Hierarchy [Digital image]. Retrieved May 27, 2022, from https://www.verywellhealth.com/types-of-doctors-residents-interns-and-fellows-3157293.

First-year residents are referred to as interns. After that, they are known as resident doctors, resident physicians, or simply "residents".

Fellowship is optional but is required to practice certain subspecialties.

Bibliographic reference: Whitlock, J. (2021, November 29). Doctors, Residents, and Attendings: What's the Difference? Verywell Health. Retrieved May 27, 2022, from https://www.verywellhealth.com/types-of-doctors-residents-interns-and-fellows-3157293.

 

Repeatability

It is a measure of precision. It is the «variation due to the measuring device. It is the variation observed when the same operator measures the same part repeatedly with the same device [1].» It «is similar to uniformity except that it deals with how consistent a particular sensor is against itself. It can be used to describe the ability of a sensor to provide the same result, under the same circumstances, over and over again [2].»

Bibliographic references:

[1] Reliawiki. 2017. Measurement System Analysis. [online] Available at: <https://reliawiki.org/index.php/Measurement_System_Analysis> [Accessed 20 February 2022].

[2] Apogeeinstruments.com. 2022. Uniformity, Repeatability, Stability, and Accuracy. [online] Available at: <https://www.apogeeinstruments.com/uniformity-repeatability-stability-and-accuracy/> [Accessed 20 February 2022].

Stability

It is «a measure of how the accuracy and precision of the system perform over time [1].»

[1]

«Stability deals with the degree to which sensor characteristics remain constant over time. Changes in stability, also known as drift, can be due to components aging, decrease in sensitivity of components, and/or a change in the signal to noise ratio, etc [2].»

Bibliographic references:

[1] Reliawiki. 2017. Measurement System Analysis. [online] Available at: <https://reliawiki.org/index.php/Measurement_System_Analysis> [Accessed 20 February 2022].

[2] Apogeeinstruments.com. 2022. Uniformity, Repeatability, Stability, and Accuracy. [online] Available at: <https://www.apogeeinstruments.com/uniformity-repeatability-stability-and-accuracy/> [Accessed 20 February 2022].

Precision

«Precision describes the variation you see when you measure the same part repeatedly with the same device. It includes the following two types of variation:

• Repeatability
• Reproducibility: variation due to the operators and the interaction between operator and part. It is the variation of the bias observed when different operators measure the same parts using the same device.»
  

Bibliographic reference: Reliawiki. 2017. Measurement System Analysis. [online] Available at: <https://reliawiki.org/index.php/Measurement_System_Analysis> [Accessed 20 February 2022].

Accuracy

«Accuracy describes the difference between the measurement and the actual value of the part that is measured. It includes:

• Bias: a measure of the difference between the true value and the observed value of a part. If the “true” value is unknown, it can be calculated by averaging several measurements with the most accurate measuring equipment available.
• Linearity: a measure of how the size of the part affects the bias of a measurement system. It is the difference in the observed bias values through the expected range of measurement [1].»

  

  [1]

It is «analogous to uncertainty relative to a reference, is in its simplest terms the difference between measured and “true” values [2].»

Bibliographic references:

[1] Reliawiki. 2017. Measurement System Analysis. [online] Available at: <https://reliawiki.org/index.php/Measurement_System_Analysis> [Accessed 20 February 2022].

[2] Apogeeinstruments.com. 2022. Uniformity, Repeatability, Stability, and Accuracy. [online] Available at: <https://www.apogeeinstruments.com/uniformity-repeatability-stability-and-accuracy/> [Accessed 20 February 2022].

Survey about a controversial breast cancer clinical case

An anonymous 9 short questions survey about a controversial breast cancer clinical case. For academic records.

Link: https://docs.google.com/forms/d/e/1FAIpQLSeZh6FqosXFlcJEDyfSHttuKkLGw18QC2rWav1HI8CwTPdzvA/viewform?vc=0&c=0&w=1&flr=0.

pMMR or dMMR

Proficient or deficient DNA (deoxyribonucleic acid) mismatch repair gene expression.

Integral dose (ID)

This is the total energy absorbed/deposited by ionizing radiation, within a body/in the treated volume (in J = kg × Gy) [1]. It is «one way of comparing dose distributions for different-quality beams. (...) If a mass of tissue receives a uniform dose, then the integral dose is simply the product of mass and dose. However, in practice, the absorbed dose in the tissue is nonuniform so rather complex mathematical formulas are required to calculate it. For a single beam of x- or γ radiation, Mayneord formulated the following expression:

Σ=1.44 D₀  A d_1⁄2 (1 - e^(0.693 d/d_1⁄2))  (1 + (2.88 d_1⁄2)/SSD)

where ∑ is the integral dose, D₀ is the peak dose along the central axis, A is the geometric area of the field, d is the total thickness of the patient in the path of the beam, d_1⁄2 is the half-value depth or the depth of 50% depth dose, and SSD is the source to surface distance. The term (1 + (2.88 d_1⁄2)/SSD) is a correction for the geometric divergence of the beam. Because the integral dose is basically the product of mass and dose, its unit is the kilogram-gray or simply joule (since 1 Gy = 1 J/kg). (...) It is generally believed that the probability of damage to normal tissue increases with the increase in the integral dose, (...) [2].»

Bibliographic references:

[1] Beyzadeoglu, M., Ozyigit, G. and Ebruli, C., 2010. Basic radiation oncology. 1st ed. Berlin: Springer, p.23.

[2] Khan, F. and Gibbons, J., 2016. Khan's the physics of radiation therapy. 5th ed. Philadelphia: Wolters Kluwer, p.181.

Addressing Radiation Oncology residency oversupply survey

The City of Hope Department of Radiation Oncology is performing an IRB (Institutional Review Board)-exempted study survey study assessing radiation oncologists’ perceptions on residency oversupply, its possible solutions, and the new ACGME (Accreditation Council for Graduate Medical Education) RCC (Review and Recognition Committee) proposed changes.

If you choose to be in the study, we will ask you to complete a survey. The survey will take about 20 minutes for you to complete. Completion of the survey will indicate your consent to be a part of the study. Your participation is voluntary, and your responses will be anonymous.

Please click on the link below if you are willing to share your thoughts with us. The link will take you to an online anonymous survey.

Survey

If you are a program coordinator receiving this survey, we kindly ask that you forward the survey to the residents.

Please contact Dr. Liu at jaliu@coh.org or Dr. Amini at aamini@coh.org or Dr. Glaser at sglaser@coh.org with questions about this study.

Best regards,

Jason Liu MD, City of Hope National Medical Center

Arya Amini MD, City of Hope National Medical Center

Scott Glaser MD, City of Hope National Medical Center

Actuarial (versus actual)

«Its use is often extended (...) to include the Kaplan-Meier (KM) method, (...). Actual is a new term (...) to refer to a technique with several designations in the statistical literature, including cumulative incidence and crude, unadjusted, absolute, or observable probability [1].»

«Actuarial analysis, (...), is used to describe and compare survival probabilities by allowing for partial survival times (censoring). (...) The actuarial event-free (survival) curve for a nonfatal event, such as structural valve deterioration (SVD) of porcine valves, estimates the event-free probability for a population in which death has been eliminated. This overestimates the percentage of valves that will actually fail, because many patients die before the valve fails [2].»

«Unlike cumulative incidence [actual estimates], the KM attempts to predict what the latent failure probability would be if death were eliminated. To do this, the KM method assumes that the risk of dying and the risk of failure are independent. But this assumption is not true for many cardiac applications in which the risks of failure and death are negatively correlated (ie, patients with a higher risk of dying have a lower risk of failure, and patients with a lower risk of death have a higher risk of failure, which is a condition called informative censoring) [3].»

«When used for nonfatal events such as SVD, actual analysis estimates the percentage of patients who will have SVD (or the probability that an individual patient will experience SVD). The KM (actuarial) method attempts to estimate the percentage of SVD that would occur if patients never died. Also, KM depends on the assumption that death and SVD are independent, which they are probably not [1].»

Bibliographic references:

[1] Grunkemeier GL, Wu Y. Actual versus actuarial event-free percentages. Ann Thorac Surg. 2001 Sep;72(3):677-8. Available at: https://doi.org/10.1016/s0003-4975(01)03059-4.

[2] Grunkemeier GL, Jamieson WR, Miller DC, Starr A. Actuarial versus actual risk of porcine structural valve deterioration. J Thorac Cardiovasc Surg. 1994 Oct;108(4):709-18. PMID: 7934107. Available at: https://doi.org/10.1016/S0022-5223(94)70298-5.

[3] Grunkemeier GL, Jin R, Eijkemans MJ, Takkenberg JJ. Actual and actuarial probabilities of competing risks: apples and lemons. Ann Thorac Surg. 2007 May;83(5):1586-92. Available at: https://doi.org/10.1016/j.athoracsur.2006.11.044.

Are you satisfied with the level of diversity, equity and inclusion in your workplace?

 

If you have not done so yet, we invite you to take this survey and let us know what challenges you have been facing in your career development. Your contribution will help us get a detailed and global picture of how the oncology workforce is doing when it comes to issues related to diversity, equity, and inclusion at work. The survey is anonymous and should take less than 15 minutes to complete. Findings will be presented at ESMO 2022. Take the survey → Thank you. ESMO Women for Oncology

Nearing the end zone: polishing your CV, cover letter, and job talk

 

QUANTEC (quantitative analysis of normal tissue effects in the clinic)

It summarizes the currently available three-dimensional dose/volume/outcome data to update and refine the normal tissue dose/volume tolerance guidelines provided by the classic "Emami" paper [1,2].

Bibliographic references:

[1] Marks LB, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9. Available at: https://doi.org/10.1016/j.ijrobp.2009.07.1754.

[2] Emami B, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22. Available at: https://doi.org/10.1016/0360-3016(91)90171-y.

NTCP (normal tissue complication probability)

Rare cancers

The definition of rare tumors is not consensual. Rare cancers are defined as an incidence of fewer than 6 cases per 100.000 individuals per year (RARECARE workin group, Gatta et al. Eur J Cancer 2011).

According to DeSantis et al. ACS Atlanta. CA Cancer J Clin 2017, overall, approximately 20% of patients with cancer in the United States are diagnosed with a rare cancer. Based on the RARECARE workin group, Gatta et al. Eur J Cancer 2011, rare cancers are about 22% of all cancer diagnoses in Europe and 24% of the total cancer prevalence.

Rare cancers include > 300 histological subtypes and may affect all organs (Morfouace et al. EORTC, ESMO Open 2020). In addition, they can be grouped within 12 families of rare cancers (Casali et al. Fondazione IRCCS INT, Milan, ESMO Open 2020):

1. Epithelial tumours of head and neck:
• Larynx;
• Hypopharynx;
• Nasal cavity and sinuses;
• Nasopharynx;
• Major salivary glands and salivary gland type tumours;
• Oropharynx;
• Oral cavity and lip;
• Eye and adnexa;
• Middle ear.
2. Epithelial digestive tumours:
• Small intestine;
• Anal canal;
• Gallbladder and extrahepatic biliary duct.
3. Thoracic tumours:
• Epithelial tumours of the trachea;
• Thymomas and thymic carcinomas;
• Malignant mesothelioma.
4. Female genital tumours:
• Non-epithelial tumours of the ovary;
• Epithelial tumours of the vulva and vagina;
• Trophoblastic tumours of the placenta.
5. Male genital and urogenital tumours:
• Tumours of the testis and paratestis;
• Epithelial tumours of penis;
• Extragonadal germ cell tumours;
• Epithelial tumours of renal pelvis, ureter, and urethra.
6. Skin cancers and non-cutaneous melanoma:
• Mucosal melanoma;
• Uveal melanoma;
• Adnexal skin carcinomas;
• Kaposi sarcoma.
7. Sarcomas:
• Soft tissue sarcoma;
• Bone sarcoma;
• Gastrointestinal stromal tumours.
8. Neuroendocrine tumours:
• Gastrointestinal pancreatic;
• Lung;
• Other sites.
9. Endocrine organ tumours:
• Thyroid cancers;
• Parathyroid cancer;
• Adrenal cortex cancer;
• Pituitary gland cancer.
10. Central nervous system tumours:
• Glial tumours and others;
• Malignant meninioma;
• Embryonal tumours.
11. Paediatric tumours:
• Hepatoblastoma;
• Neuroblastoma and ganglioneuroblastoma;
• Nephroblastoma;
• Odontogenic malignant tumours;
• Olfactory neuroblastoma;
• Pancreatoblastoma;
• Pleuropulmonary blastoma;
• Retinoblastoma.
12. Haematological malignancies:
• Lymphoid malinancies;
• Myelodysplasctic syndromes;
• Myeloproliferative neoplasms (including mastocytosis);
• Myelodysplastic/myeloproliferative neoplasms;
• Myeloid/lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA (platelet derived growth factor receptor alpha), PDGFRB (platelet derived growth factor receptor beta), or FGFR1 (fibroblast growth factor receptor 1), or with PCM1-JAK2 (pericentriolar material 1-janus kinase 2);
• Acute myeloid leukaemia and related neoplasms.

Then, rare cancers are not so rare, and they are associated with multiple challenges including late and incorrect diagnosis, adverse outcomes, limited clinical expertise, weak evidence for best practice, and difficulties in collecting large series for research and in carrying out clinical trials (Boyd et al. BCCA, Vancouver, Lancet Oncol 2016).

Therefore, a global strategy is needed to join efforts to increase knowledge of this group of cancers.

Survey on data protection and informed consent in clinical research during the COVID-19 pandemic

Survey on data protection and informed consent in clinical research during the COVID-19 pandemic

Ask a Radiation Oncologist: Radiation Therapy for upper gastrointestinal (GI) cancers

 

Where must Radiation Oncology go first in the 2020s?

 

Stereotactic radiation therapy of choroidal melanoma